<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799521</url>
  </required_header>
  <id_info>
    <org_study_id>15989</org_study_id>
    <nct_id>NCT05799521</nct_id>
  </id_info>
  <brief_title>A Nasal Treatment for COVID-19</brief_title>
  <acronym>COVD-TX</acronym>
  <official_title>A Novel Nasal Treatment for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test an investigational new inhaled medication called Optate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to test an investigational new inhaled medication called Optate.&#xD;
      Investigational means it has not been approved by the Food and Drug Administration (FDA) for&#xD;
      this use. The investigators hypothesize that Optate will reduce the length of symptoms and&#xD;
      disease severity in patients with COVID-19 (Coronavirus disease of 2019) through inhibition&#xD;
      of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) viral replication within the&#xD;
      upper and lower airways. Testing this hypothesis is important because treatments for COVID-19&#xD;
      are needed alongside vaccines. COVID-19 begins in the nasal passages, so targeted therapies&#xD;
      to the nasal passages at early stages of the disease may prevent severe disease from&#xD;
      occurring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>People who test positive for COVID-19</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Providing pharmacy will randomize doses and provide blinded doses</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Clinical Respiratory Viral panels and SARS-CoV-2 Levels</measure>
    <time_frame>6 months after enrollment opens</time_frame>
    <description>Clinical respiratory viral panels and SARS-CoV-2 levels will be measured in nasal wash before and one hour after Optate or placebo administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survey assessment</measure>
    <time_frame>6 months after enrollment closes</time_frame>
    <description>3.1.2 SNOT-22 scores (a validated, 22-item quality of life instrument survey) will be assessed immediately prior to Optate or placebo administration. Scores will be reassessed one hour after administration and 24 hours after administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects on Treatment arm will get study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects on Treatment arm will get placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optate</intervention_name>
    <description>Alkaline Buffer</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Glycine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects, 18 and above, with mild COVID-19 upper respiratory tract&#xD;
        infection symptoms&#xD;
&#xD;
          -  positive rapid COVID-19 test&#xD;
&#xD;
          -  Ordinal Scale for Clinical Improvement &lt; 3 (OSCI, Appendix 2) and/or&#xD;
&#xD;
          -  Fever &gt; 100 degree F and/or&#xD;
&#xD;
          -  Nasal congestion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1 (Forced Exhaled Volume) &lt; 55% predicted on the day of study procedures&#xD;
&#xD;
          -  OSCI â‰¥ 3 (Objective Structured Clinical Exam)&#xD;
&#xD;
          -  Inability to follow commands or perform study procedures including spirometry,&#xD;
             coordinated inhalation of study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bre Bohart</last_name>
    <phone>317-626-6937</phone>
    <email>IUpulm@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenzie Mahan</last_name>
    <phone>317-274-8899</phone>
    <email>krmahan@iu.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Davis MD, Donn SM, Ward RM. Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient. Paediatr Drugs. 2017 Jun;19(3):183-192. doi: 10.1007/s40272-017-0221-9.</citation>
    <PMID>28374138</PMID>
  </reference>
  <reference>
    <citation>Davis MD, Hunt J. Exhaled breath condensate pH assays. Immunol Allergy Clin North Am. 2012 Aug;32(3):377-86. doi: 10.1016/j.iac.2012.06.003. Epub 2012 Jul 10.</citation>
    <PMID>22877616</PMID>
  </reference>
  <reference>
    <citation>Davis MD, Walsh BK, Dwyer ST, Combs C, Vehse N, Paget-Brown A, Pajewski T, Hunt JF. Safety of an alkalinizing buffer designed for inhaled medications in humans. Respir Care. 2013 Jul;58(7):1226-32. doi: 10.4187/respcare.01753. Epub 2012 Dec 18.</citation>
    <PMID>23258576</PMID>
  </reference>
  <reference>
    <citation>Hunt JF, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TA, Gaston B. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):694-9. doi: 10.1164/ajrccm.161.3.9911005.</citation>
    <PMID>10712309</PMID>
  </reference>
  <reference>
    <citation>Ngamtrakulpanit L, Yu Y, Adjei A, Amoah G, Gaston B, Hunt J. Identification of Intrinsic Airway Acidification in Pulmonary Tuberculosis. Glob J Health Sci. 2010 Apr;2(1):106-110. doi: 10.5539/gjhs.v2n1p106.</citation>
    <PMID>21197384</PMID>
  </reference>
  <reference>
    <citation>Ricciardolo FL, Gaston B, Hunt J. Acid stress in the pathology of asthma. J Allergy Clin Immunol. 2004 Apr;113(4):610-9. doi: 10.1016/j.jaci.2003.12.034.</citation>
    <PMID>15100663</PMID>
  </reference>
  <reference>
    <citation>Shin HW, Shelley DA, Henderson EM, Fitzpatrick A, Gaston B, George SC. Airway nitric oxide release is reduced after PBS inhalation in asthma. J Appl Physiol (1985). 2007 Mar;102(3):1028-33. doi: 10.1152/japplphysiol.01012.2006. Epub 2006 Nov 16.</citation>
    <PMID>17110506</PMID>
  </reference>
  <reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </reference>
  <reference>
    <citation>Paget-Brown AO, Ngamtrakulpanit L, Smith A, Bunyan D, Hom S, Nguyen A, Hunt JF. Normative data for pH of exhaled breath condensate. Chest. 2006 Feb;129(2):426-430. doi: 10.1378/chest.129.2.426.</citation>
    <PMID>16478862</PMID>
  </reference>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 24, 2023</study_first_submitted>
  <study_first_submitted_qc>April 4, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>James F. Chmiel</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

